Education
About Us
Working with TipRanks
Follow Us
IBB - ETF AI Analysis
Top Page
iShares Biotechnology ETF (IBB)
Rating:66Neutral
Price Target:―
Positive Factors
Focused Exposure to Biotechnology Leaders
The fund’s largest positions are well-known biotech companies, giving investors targeted access to major players in the industry.
Recent Performance Momentum
The ETF has shown solid gains over the last few months, indicating improving short-term performance despite some recent pullbacks.
Large Asset Base
With several billion dollars in assets, the fund is sizable and established, which can support better trading liquidity for investors.
Negative Factors
High Sector Concentration
Almost all of the ETF is invested in health care and specifically biotechnology, making it very sensitive to swings in that single industry.
Mixed Performance Among Top Holdings
Several of the largest positions have been weak so far this year, which can drag on the fund’s overall returns.
Above-Average Expense Ratio
The fund’s fee is on the higher side for an ETF, which slightly reduces the net return that investors keep over time.
IBB vs. SPDR S&P 500 ETF (SPY)
AUM8.77B
RegionNorth America
Expense Ratio0.44%
Beta0.80
IssueriShares
Inception DateFeb 05, 2001
Dividend Yield0.22%
Asset ClassEquity
Index TrackedNYSE Biotechnology (TR)
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume1,659,735
30 Day Avg. Volume2,070,193
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
215.60Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering249
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IBB Summary
The iShares Biotechnology ETF (IBB) is a fund that follows the NYSE Biotechnology Index, focusing on U.S. biotech companies working on new drugs and medical treatments. It holds well-known names like Amgen and Gilead Sciences, along with many smaller firms developing cutting-edge therapies. Someone might invest in IBB to seek long-term growth from medical innovation while spreading risk across many biotech stocks instead of picking just one company. However, biotech shares can be very volatile, so the value of this ETF can rise and fall sharply with news about drug trials, approvals, or the overall market.
How much will it cost me?The iShares Biotechnology ETF (IBB) has an expense ratio of 0.44%, which means you’ll pay $4.40 per year for every $1,000 invested. This is slightly higher than average because it’s a sector-focused fund that requires more active management to track the biotechnology industry. It’s a reasonable cost for the specialized exposure it provides.
What would affect this ETF?The iShares Biotechnology ETF (IBB) could benefit from advancements in medical research, increased demand for innovative treatments, and supportive government policies for health care innovation. However, it may face challenges from regulatory hurdles, high development costs, and potential market volatility tied to interest rate changes or broader economic conditions. Its focus on U.S.-listed biotechnology companies means it is heavily influenced by trends in the U.S. health care sector and the performance of top holdings like Gilead Sciences and Vertex Pharmaceuticals.
IBB Top 10 Holdings
IBB is very much a U.S. biotech story, with a heavy tilt toward a handful of big drug developers that set the tone for the fund. Amgen and Regeneron have been the main engines lately, with rising share prices over the past few months helping to pull the ETF higher. Vertex and Gilead are more mixed, wobbling recently and adding some chop to returns. On the weaker side, Alnylam and Insmed have been lagging, acting like a headwind and highlighting how concentrated the fund is in higher‑risk biotech names.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals | 8.60% | $744.24M | $118.84B | 6.55% | 78 Outperform | |
| Gilead Sciences | 8.60% | $744.19M | $168.65B | 46.05% | 78 Outperform | |
| Amgen | 7.94% | $687.53M | $185.64B | 25.17% | 77 Outperform | |
| Regeneron | 6.48% | $561.11M | $79.20B | 11.51% | 78 Outperform | |
| Alnylam Pharma | 3.95% | $341.83M | $47.29B | 28.42% | 60 Neutral | |
| Argenx Se | 2.80% | $242.66M | $51.30B | 25.55% | 79 Outperform | |
| Insmed | 2.79% | $241.75M | $33.32B | 99.04% | 43 Neutral | |
| Natera | 2.70% | $233.48M | $33.42B | 44.13% | 73 Outperform | |
| Biogen | 2.14% | $184.92M | $25.17B | 17.37% | 74 Outperform | |
| BeOne Medicines | 2.09% | $180.54M | $42.18B | 52.79% | 61 Neutral |
IBB Technical Analysis
Positive
―
Price Trends
169.90
Positive
159.44
Positive
143.41
Positive
Market Momentum
1.56
Negative
58.17
Neutral
85.94
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IBB, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 171.88, equal to the 50-day MA of 169.90, and equal to the 200-day MA of 143.41, indicating a bullish trend. The MACD of 1.56 indicates Negative momentum. The RSI at 58.17 is Neutral, neither overbought nor oversold. The STOCH value of 85.94 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IBB.
IBB Peer Comparison
Comparison Results
Performance Comparison
IBB
iShares Biotechnology ETF
175.33
37.31
27.03%
XBI
SPDR S&P BIOTECH ETF
―
―
―
IHI
iShares U.S. Medical Devices ETF
―
―
―
IYH
iShares U.S. Healthcare ETF
―
―
―
FHLC
Fidelity MSCI Health Care Index ETF
―
―
―
FBT
First Trust NYSE Arca Biotechnology Index Fund
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents